Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 8
Submit an article Journal homepage
527
Views
7
CrossRef citations to date
0
Altmetric
Review

Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review

R. Scottoa Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
,
A. Reiab Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, University of Naples Federico II, ItalyView further author information
,
A.R. Buonomoa Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
View further author information
,
M. Mocciab Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, University of Naples Federico II, ItalyView further author information
,
G. Vicecontea Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
,
E. Pisanob Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, University of Naples Federico II, ItalyView further author information
,
E. Zappuloa Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
,
V. Brescia Morrab Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, University of Naples Federico II, ItalyView further author information
&
I. Gentilea Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
 show all
Pages 925-936 | Received 05 Jan 2021, Accepted 14 Apr 2021, Published online: 21 Apr 2021

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Chiara Rosa Mancinelli, Nicola De Rossi & Ruggero Capra. (2021) Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Therapeutics and Clinical Risk Management 17, pages 765-776.
Read now

Articles from other publishers (6)

Yagmur Tasdemiroglu, Robert G. Gourdie & Jia-Qiang He. (2022) In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases. European Journal of Pharmacology 932, pages 175192.
Crossref
Emanuela Zappulo, Antonio Riccardo Buonomo, Marcello Moccia, Biagio Pinchera, Riccardo Villari, Maria Petracca, Roberta Lanzillo, Riccardo Scotto, Antonio Carotenuto, Giulio Viceconte, Nicola Schiano Moriello, Luca Bruno, Ivan Gentile & Vincenzo Brescia Morra. (2022) Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. Multiple Sclerosis and Related Disorders 63, pages 103814.
Crossref
Marcello Moccia, Giuseppina Affinito, Bruno Ronga, Roberta Giordana, Maria Grazia Fumo, Roberta Lanzillo, Maria Petracca, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra & Raffaele Palladino. (2022) Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). Multiple Sclerosis Journal 28:4, pages 597-607.
Crossref
Océane Perdaens & Vincent van Pesch. (2022) Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis. Frontiers in Neurology 12.
Crossref
A. Klein, A. Berthele & B. Hemmer. (2021) Cryptococcal meningitis in a multiple sclerosis patient treated with dimethylfumarate. Neuroimmunology Reports 1, pages 100024.
Crossref
Andreas K. Jaklin, Espen Benjaminsen & Karl B. Alstadhaug. (2021) Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort. Frontiers in Neurology 12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.